Skip to main
SPTX

SPTX Stock Forecast & Price Target

SPTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Seaport Therapeutics is poised for success due to its strong financial backing and promising pipeline of novel treatments for depression and anxiety. The company has a unique technology, Glyph, which can improve drug efficacy and safety, making it a competitive player in the market. The company's focus on addressing unmet needs in the neuropsychiatry field has the potential for significant growth and profitability. However, there are potential risks and challenges, as seen with the failure of a phase 3 trial for zuranolone, and the company will need to continue delivering successful clinical results to maintain investor confidence.

Bears say

Seaport Therapeutics is a clinical-stage biopharmaceutical company that is focused on utilizing its lymphatic-targeting prodrug technology, Glyph, to enhance the oral bioavailability and reduce side effects of existing treatments for neuropsychiatric disorders. The company's pipeline includes lead candidate GlyphAllo, a potential treatment for major depressive disorder (MDD) and generalized anxiety disorder (GAD), which has shown positive results in Phase 1 and 2 clinical trials. However, the company's success in these markets is dependent on significant commercial infrastructure and highly differentiated clinical impact, and competition in the pharmaceutical industry is highly litigious. The company's management team, including CEO Daphne Zohar, has a successful track record in the industry, but the effectiveness of their IP protection strategies and reliance on partnerships for international sales are potential red flags.

SPTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Seaport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Seaport Therapeutics Inc (SPTX) Forecast

Analysts have given SPTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, SPTX has a Strong Buy consensus rating as of Jul 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Seaport Therapeutics Inc (SPTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.